Latest News - Biogen
Top Corporates Hub
Biogen
EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton
09.06.2026 12:16
EVERSANA®, a leading global provider of commercial services to the life sciences industry, today announced the expansion of its already leading market access offering with the appointment of Jen Norton as President, Market Access & Value. In this new role, Norton will lead the development of a dedicated, technology-first fully integrated market access business unit, uniting EVERSANA's comprehensive services to help clients navigate the complex global pricing and access landscape.
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
04.06.2026 05:00
Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observe
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
03.06.2026 11:30
Data presentations across multiple kidney diseases illustrate the breadth of Biogen’s nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal antibody. CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that fourteen abstracts highlighting data from its nephrology portfolio, including EMPAVELI® (pegcetacoplan) and investigational felzartamab, have been accepted for presentation at the 63rd European Renal A
Sobi to present new data on pegcetacoplan at ERA 2026
01.06.2026 08:19
Sobi® today announced that new data from the pegcetacoplan clinical development programme and related research in C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) will be presented at the 63rd Congress of the European Renal Association (ERA), taking place from 3 - 6 June 2026 in Glasgow, UK. Presentations will be made in collaboration with Apellis Pharmaceuticals (now part of Biogen).
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
01.06.2026 05:30
Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus placebo plus standard of careFindings showed results in favor of dapirolizumab pegol plus standard of care versus placebo plus standard of care across endpoints, including multiple disease activity measures, severe flares, patient-reported outcomes, including fatigue, and glucocort
UCB and Biogen Report Late-Stage Lupus Trial Results for Experimental Drug
01.06.2026 04:40
UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) today announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS GO clinical trial
RBC Capital Maintains Outperform on Biogen, Raises Price Target to $227
27.05.2026 10:34
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $222 to $227.
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
26.05.2026 00:06
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
19.05.2026 10:30
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" W. Bonney, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective May 16, 2026. Simona Skerjanec, M.Pharm, MBA, will transition from Interim Chairperson to continue serving as a member of the Board.
How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus
19.05.2026 04:34
Alector’s updated analyst framework now points to a fair value move from US$2.88 to US$3.10, a modest shift that still signals a meaningful recalibration of expectations. This change is closely tied to how analysts are weighing CELIA’s readthrough for tau-targeting therapies and Alector’s pivot toward blood brain barrier shuttle based designs, balancing the scientific promise against execution risks and the memory of prior trial setbacks. As you read on, you will see how to track these moving...
BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations
18.05.2026 09:03
Biogen Phase 2 CELIA trial data sent shares down 6.4% after it was revealed that topline data missed its primary endpoint.NEW YORK, May 18, 2026 /PRNewswire/ -- Biogen Inc. shareholders lost 6.4% per...
Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls
15.05.2026 13:45
Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls
Biogen completes $5.3B Apellis Pharmaceuticals acquisition
15.05.2026 11:44
Apellis, maker of eye disease drug SYFOVRE and kidney drug EMPAVELI, is now a wholly owned Biogen subsidiary
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity
15.05.2026 11:10
Biogen Inc. upgraded to Hold: Apellis deal adds revenue, MS stable but pipeline delays persist. Click for this updated look at BIIB following Q1 earnings.
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer's Pathologies in Biogen's Phase 2 Tau Study
15.05.2026 00:48
Today, Biogen announced topline results from the Phase 2 CELIA study of diranersen, an investigational therapy designed to target tau in people with early Alzheimer's disease. While the study did not meet its primary endpoint, Biogen reported reductions in tau and signals of slowed cognitive decline and plans to advance the drug into further trials.
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
14.05.2026 11:05
CARLSBAD, Calif., May 14, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer’s disease (AD). The CELIA results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impact an
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
14.05.2026 10:59
CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational developmentRobust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study1Pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly at the lowest doseThe safety and tol
Biogen to advance experimental Alzheimer's drug despite mid-stage trial miss
14.05.2026 08:08
Biogen said on Thursday itwas advancing its experimental Alzheimer’s drug to late-stagetrials despite the treatment failing to meet the main goal of amid-stage study. Shares of the...